CASE STUDY
Custom API solutions help accelerate drug discovery at Calibr-Skaggs
Industry
Nonprofit Translational Research
Solution
CAS Custom Service℠
KEY RESULT
Real-time
Compound similarity searches within existing systems
KEY RESULT
↓
Manual research time per compound decision
KEY RESULT
Day 1
Immediate team adoption upon launch
The Challenge
Disparate data and fragmented workflows slow a high-impact drug discovery pipeline
Calibr-Skaggs Institute for Innovative Medicines is a leading nonprofit translational research center focused on advancing drug discovery, from early-stage compound screening through to human proof-of-concept studies across a wide range of diseases and modalities. For organizations working at this pace and scale, quickly determining which compounds to prioritize for development is critical. These decisions directly shape research efficiency, resource allocation, and ultimately the speed at which potentially life-saving treatments can reach patients.
Calibr-Skaggs faced a set of interconnected challenges slowing these processes across its discovery pipeline: inefficient manual workflows, limited access to integrated contextual information on promising compounds, and fragmented hand-offs between teams. The cumulative effect was reduced confidence in go/no-go decisions, higher risk at key pipeline stages, and slower overall innovation. Recognizing the need for greater automation and richer data context, the team sought a partner who could design a solution that fit seamlessly into their existing systems.
The Solution
A tailored CAS API solution streamlines critical parts of the drug discovery workflow
In close collaboration with Calibr-Skaggs' team, CAS Custom Services designed a tailored API solution to support and streamline the early stages of the discovery pipeline, from hit discovery through candidate selection. The solution automatically generates reports on candidate compounds through structure similarity queries, enabling researchers to run real-time compound similarity searches and in silico screening directly within their existing systems. This automation delivers enriched metadata and faster insights at scale, reducing the time scientists spend on manual research and enabling more informed decisions earlier in the pipeline.
The solution also addressed the fragmentation between Calibr-Skaggs' cross-functional teams. By enabling medicinal chemists and biologists to work in parallel rather than sequentially, the API eliminated delays caused by siloed validation steps, adding consistency and real-time collaboration to workflows that had previously operated in isolation.
The Outcome
CAS-quality insights, integrated from day one
Through its partnership with CAS, Calibr-Skaggs was able to integrate high-quality chemical insights directly into its internal processes without disrupting an active pipeline. Researchers gained the ability to evaluate and prioritize compounds with greater speed and confidence, and cross-functional teams gained a shared, real-time view of compound data that had previously been difficult to access and act on together. The result is a meaningfully faster, more connected drug discovery process that helps translate scientific promise into patient impact more efficiently.
Schedule a free CAS Custom Services℠ consultation
Your privacy is important to CAS. More detail about how we use your information is in our privacy policy.